• Multiple Diagnosis, Solide Tumores
    First –in human, dose-escalating safety study of tissue factor specific antibody drug conjugate(Humax-TF-ADC) in patients with locally advanced and/or metastatic solid tumors known to express tissue factor
  • Lung Cancer, Melanoma, Thyroid Cancer
    Open label multicenter Phase I/II study of the safety and efficacy of PDR001 administered to patients with advanced malignancies
  • Solide Tumores
    A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors”


Norway Norway Sweden Finland Aarhus Herlev Copenhagen